Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk
Launched by JOHNS HOPKINS UNIVERSITY · Sep 13, 2005
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying new imaging techniques, specifically magnetic resonance imaging (MRI) and computed tomography (CT), to better understand the risk factors for sudden cardiac death. Sudden cardiac death can happen to anyone and is becoming more common, but it’s often hard to know who is at the greatest risk. The researchers aim to find out if these imaging methods can help identify people who may be at higher risk for this serious event.
To participate in this study, individuals should be between 65 and 74 years old and have a specific heart condition where the heart's pumping ability is reduced (known as a left ventricular ejection fraction of 35% or lower). They also need to be planning to have a device called an implantable cardioverter-defibrillator (ICD) put in for protection against sudden death. However, people who have a history of sudden death or cannot undergo an MRI due to certain medical devices (like a pacemaker) are not eligible. Participants can expect to undergo imaging tests and will contribute to important research that could help save lives in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Left ventricular ejection fraction \<or = 35%
- • Planned implantable cardioverter-defibrillator (ICD) implantation for clinical indications (primary prevention)
- Exclusion Criteria:
- • History of sudden death (secondary prevention)
- • Contraindication to undergoing MRI (metallic implant, pacemaker, etc.)
About Johns Hopkins University
Johns Hopkins University, a prestigious research institution located in Baltimore, Maryland, is renowned for its commitment to advancing medical science and public health through innovative clinical trials. With a rich history of groundbreaking research and a multidisciplinary approach, the university's clinical trial initiatives focus on translating scientific discoveries into effective treatments and interventions. Leveraging state-of-the-art facilities and a collaborative network of experts, Johns Hopkins University conducts rigorous clinical studies that aim to improve patient outcomes and address critical health challenges. Its dedication to ethical standards and participant safety underscores its role as a leader in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Katherine C Wu, MD
Principal Investigator
Johns Hopkins University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials